NEW YORK (GenomeWeb News) – GE Healthcare and BGI today announced a multi-year research collaboration to explore the underlying genetic variation between ethnically diverse human stem cell lines.
The goal of the deal, whose terms were not disclosed, is to advance the use of stem cell-derived assays in drug discovery and toxicity testing.